Scholar Rock Holding Corp SRRK

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy ("SMA") and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta ("TGFβ") superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Based on our innovative, proprietary, and scalable technology platform, we are building a world-leading anti-myostatin pipeline. During 2025, we made significant progress in advancing our product candidates. We believe 2026 could be a transformational year for Scholar Rock as we anticipate the potential to become a commercial-stage biotech company.

Last close 41.49 2026-10-23
Market cap $5.05B 2026-06-30 share count
52-week range 27.07 - 61.76

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.29

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $0——$33.2M$18.8M$15.4M$20.5M$0——
R&D $208.4M$184.6M$121.9M$124.4M$108.5M$74.1M$54.2M$36.3M$19.9M—
SG&A $176.2M$67.5M$49.4M$43.1M$40.3M$28.2M$20.8M$14.4M$5.1M—
Total operating expenses $384.6M$252.1M$171.3M$167.6M$148.7M$102.3M$75.0M$50.7M$25.0M—
Operating income -$384.6M-$252.1M-$171.3M-$134.4M-$129.9M-$86.9M-$54.5M-$50.7M-$25.0M—
Interest expense $6.9M$6.8M—————$1.4M$44.0K—
Net income -$378.0M-$246.0M-$166.0M-$134.5M-$131.8M-$86.5M-$51.0M-$49.3M-$25.0M—
EPS, basic -3.29-2.47-1.99-2.26-3.59-2.81————
EPS, diluted -3.29-2.47-1.99-2.26-3.59-2.81-1.85-3.15-15.30—
Shares, diluted (wtd. avg.) 114.7M99.8M83.3M59.6M36.7M30.7M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $323.5M$177.9M$104.3M$105.8M$215.3M$162.9M$38.8M$115.3M$56.7M$10.2M
Short-term investments $44.0M$259.4M$178.1M$212.1M$40.2M$180.7M$121.1M$60.6M$1.5M—
Receivables ——————$25.0M———
Total current assets $385.1M$451.2M$288.2M$328.0M$265.3M$344.4M$185.2M$177.9M$59.2M—
Property, plant and equipment $1.7M$2.8M$4.6M$7.4M$9.6M$8.1M$4.2M$3.2M$2.2M—
Total assets $404.3M$474.9M$311.0M$358.2M$304.4M$388.3M$196.4M$181.3M$61.6M—
Accounts payable $10.3M$10.1M$3.5M$4.0M$4.4M$3.4M$1.1M$3.3M$1.4M—
Short-term debt ——$1.3M—$1.6M—————
Total current liabilities $55.4M$46.9M$32.7M$36.4M$64.3M$42.6M$32.8M$31.1M$5.0M—
Long-term debt $99.7M$50.1M$48.7M$49.7M$48.4M$24.7M————
Total liabilities $158.8M$106.3M$85.8M$97.9M$132.4M$127.5M$83.5M$74.7M$5.9M—
Retained earnings -$1.30B-$922.7M-$676.4M-$510.6M-$376.1M-$244.3M-$157.8M-$106.8M-$57.5M—
Total equity $245.5M$368.6M$225.2M$260.2M$172.1M$260.8M$112.9M$106.6M-$53.5M-$30.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$300.0M-$200.9M-$145.2M-$132.7M-$126.8M-$60.3M-$63.1M$24.6M-$21.7M—
Stock-based compensation $75.6M$36.6M$27.1M$27.7M$23.1M$11.2M$8.0M$5.2M$1.5M—
Capital expenditure $602.0K$98.0K$71.0K$1.1M$5.2M$4.1M$3.1M$1.5M$361.0K—
Investing cash flow $218.7M-$76.1M$41.1M-$171.7M$134.3M-$63.5M-$62.2M-$60.2M$17.7M—
Financing cash flow $228.4M$353.0M$102.6M$194.8M$45.0M$247.8M$48.9M$94.3M$50.5M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-046917.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M Net income, FY2017: -25M Revenue, FY2018: 0 Net income, FY2018: -49.3M Revenue, FY2019: 20.5M Net income, FY2019: -51M Revenue, FY2020: 15.4M Net income, FY2020: -86.5M Revenue, FY2021: 18.8M Net income, FY2021: -131.8M Revenue, FY2022: 33.2M Net income, FY2022: -134.5M Net income, FY2023: -166M Net income, FY2024: -246M Revenue, FY2025: 0 Net income, FY2025: -378M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — $0 $20.5M $15.4M $18.8M $33.2M — — $0
Gross profit — — — — — — — — — —
Net income — -$25.0M -$49.3M -$51.0M -$86.5M -$131.8M -$134.5M -$166.0M -$246.0M -$378.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%